Uncategorized

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

Jemincare announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration and 2 approvals from the U.S. Food & Drug Administration.

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs Read More »

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets Read More »

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets Read More »

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases Read More »

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca.

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases Read More »

Scroll to Top